CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

1. Diagnosis: Age 18-80 years with diagnosis of:

   1. Relapsed or refractory AML or "treated secondary AML"

      * Patients with a mutation that is targetable with an FDA-approved targeted therapy should have received at least one on these agents. . "Treated secondary AML "includes patients with prior diagnosis of a myeloid neoplasm (e.g. MDS) who received hypomethylating agents for this disease and subsequently progressed to AML. These patients must have received all of the following: a hypomethylating agent + venetoclax and intensive chemotherapy (if a suitable candidate for intensive therapy). These patients may be enrolled at the time of AML diagnosis if they have already received all of the treatments above for their antecedent myeloid neoplasm.
   2. MDS that is intermediate, high-risk or very-high risk by the Revised International Prognostic Scoring System (R-IPSS)

      * Bone marrow blasts must be \>5%.
      * The disease must have either 1.) not have responded to at least 4 cycles of a hypomethylating agent or 2.) progressed or relapsed, regardless of the number of cycles received
   3. CMML-1 or CMML-2

      * Bone marrow blasts must be \>5%.
      * The disease must have either 1.) not have responded to at least 4 cycles of a hypomethylating agent or 2.) progressed or relapsed, regardless of the number of cycles received
2. CD70 expression \>10% measured by immunohistochemistry or multiparameter flow cytometry
3. Performance status \</=2 (ECOG Scale)
4. Adequate liver, cardiac, renal and pulmonary function as defined by the following criteria:

   1. Total serum bilirubin \</=2 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI
   2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \</=3 x ULN, unless due to the underlying leukemia approved by the PI
   3. Serum creatinine \</=2x ULN or creatinine clearance \>/=30 mL/min
   4. Left ventricular ejection fraction \>/=40% by echocardiogram or MUGA
   5. Oxygen saturation \>/=93% on room air
5. Ability to understand and the willingness to sign a written informed consent document
6. Willingness to sign informed consent to long-term follow-up on protocol PA17-0483 to fulfill institutional responsibilities to regulatory agencies
7. Willingness to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study participation. For women of childbearing potential, adequate methods of contraception include: complete abstinence,, hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post vasectomy, implantable or injectable contraceptives, and condoms plus spermicide.

Exclusion Criteria:

1. Active grade III-V cardiac failure as defined by the New York Heart Association Criteria
2. Active serious infection not controlled by oral or intravenous antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment).
3. Active central nervous system leukemia
4. Known human immunodeficiency virus (HIV) seropositive, unless well-controlled on stable doses of anti-retroviral therapy.
5. Known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.
6. Patients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI
7. Use of calcineurin inhibitors (e.g. tacrolimus) within the past 2 weeks
8. Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before lymphodepletion, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.

   i. Prior recent treatment with corticosteroids, hydroxyurea, and/or cytarabine (up to 2 g/m2 given for cytoreduction within the preceding 7 days) is permitted up until 1 day prior to lymphodepletion.

   • Patients may continue on non-investigational targeted therapies up until 3 days prior to lymphodepletion.
9. Pregnant or breastfeeding women will not be eligible

主要终点：Safety and Adverse Events (AEs) · Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 · Through study completion; an average of 1 year；Response rates (AML cohort) · Rate of complete remission (CR) + CR with incomplete hematologic recovery (CRi) + CR with CR with partial hematologic recovery (CRh) · 30 days from CAR infusion；Response rates (MDS/CMML) cohort · Rate of CR + partial remission (PR) + CR with limited count recovery (CRL), CRh, hematologic improvement (HI) for MDS; rate of CR + PR + marrow CR (mCR) + clinical benefit (CB) for CMML · 30 days from CAR infusion
次要终点：CR rate；Measurable residual disease (MRD) negativity (AML cohort)；Duration of response；Relapse-free survival；Overall survival；Hematologic and non-hematologic toxicities

• Phase 1: Dose Escalation with CAR.70 · EXPERIMENTAL · Participants will receive lymphodepleting and primary chemotherapy, followed by a one-time infusion of TGFR KO-CAR27/IL-15 NK cells. Dose of the cells will be a different dose until a maximum tolerated dose is found.
• Phase 2A: Dose Expansion with CAR.70 for AML Patients · EXPERIMENTAL · Participants will receive lymphodepleting and primary chemotherapy, followed by a one-time infusion of TGFR KO-CAR27/IL-15 NK cells using the maximum tolerated dose found in escalation

The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.